Liver cirrhosis in 2021: Global Burden of Disease study
PLOS One · 18.07.2025 · 20 (7) · e0328493
DOI: 10.1371/journal.pone.0328493 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 18.07.2025. Verfasst von Hong Duo und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Global Burden of Disease. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Liver cirrhosis is a chronic progressive disease caused by various liver injury mechanisms, characterized by irreversible fibrosis, hepatocyte degeneration and necrosis, and the formation of regenerative nodules, ultimately leading to liver failure and multiple severe complications, significantly increasing the risk of mortality.
Methods
This study analyzes global and China-specific trends in liver cirrhosis incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021, focusing on various causes including hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Data from the Global Burden of Disease (GBD) database were used to assess changes in liver cirrhosis statistics globally and in China. The study examined incidence, prevalence, mortality, and DALYs over the period from 1990 to 2021.
Results
Global liver cirrhosis incidence reached 58.4 million in 2021, up from 36.9 million in 1990, primarily driven by NAFLD, which increased from 24.8 million in 1990 to 48.3 million in 2021. While HBV- and HCV-related cirrhosis declined, deaths from alcoholic cirrhosis rose. In China, NAFLD became the main cause, although alcohol-related cirrhosis and an aging population remain major challenges.
Conclusions
The growth of NAFLD and alcohol-related cirrhosis undermines progress in controlling HBV and HCV. Targeted prevention and management strategies are needed, especially in regions with low and middle SDI, which show higher cirrhosis mortality. For China, early intervention for NAFLD and continued control of HBV and HCV are critical to reduce the cirrhosis burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research Center for Natural Polymer Biological Liver, Hubei Engineering Center…
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
- Transplant Intensive Care Unit, Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Labo…
ORCID-Profile: Hong Duo
Zitieren
APA
Duo, H., You, J., Du, S., Yu, M., Wu, S., Yue, P., Cui, X., Huang, Y., Luo, J., Pan, H., & Ye, Q. (2025). Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One, 20(7), e0328493. https://doi.org/10.1371/journal.pone.0328493
Vancouver
Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025;20(7):e0328493. doi:10.1371/journal.pone.0328493
BibTeX
@article{Duo2025,
author = {Duo, Hong and You, Jian and Du, Siqi and Yu, Mengran and Wu, Shaomei and Yue, Pengpeng and Cui, Xiao and Huang, Yihui and Luo, Jun and Pan, Huaqin and Ye, Qifa},
title = {Liver cirrhosis in 2021: Global Burden of Disease study},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0328493},
doi = {10.1371/journal.pone.0328493}
}
EUVIMED